



April 5, 2013

Merrimack Pharmaceuticals Announces Webcast of Inaugural Research & Development Day

CAMBRIDGE, Mass., April 5, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it will hold its inaugural Research & Development Day for analysts and the investor community on Thursday, April 11, 2013 from 9:30 a.m. to 1:00 p.m. ET. Members of Merrimack's management team will provide in-depth reviews of the company's scientific approach, as well as an overview of the company's pipeline, focusing on the later stage programs.

A live webcast of the presentation can be accessed by visiting the investor relations section of the company's website at investors.merrimackpharma.com. A replay of the webcast will be archived on Merrimack's website for six weeks following the presentation.

About Merrimack Pharmaceuticals, Inc.

Merrimack Pharmaceuticals is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has six targeted therapeutic oncology candidates in clinical development.

Forward-Looking Statement

Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.

CONTACT: Media Contacts:

Kathleen Petrozzelli Gallagher, Merrimack

617-441-1043

kgallagher@merrimackpharma.com

Liz Bryan, Spectrum

202-955-6222

lbryan@spectrumscience.com

Source: Merrimack Pharmaceuticals

News Provided by Acquire Media